Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-Current Assets (2020 - 2025)

Cytek Biosciences' Non-Current Assets history spans 6 years, with the latest figure at $69.5 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 32.51% year-over-year to $69.5 million; the TTM value through Dec 2025 reached $388.6 million, down 4.56%, while the annual FY2025 figure was $69.5 million, 32.51% down from the prior year.
  • Non-Current Assets reached $69.5 million in Q4 2025 per CTKB's latest filing, down from $106.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $110.5 million in Q2 2025 to a low of $3.9 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $56.7 million, with a median of $69.5 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: skyrocketed 1138.08% in 2023, then plummeted 32.51% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $5.9 million in 2021, then soared by 133.84% to $13.7 million in 2022, then skyrocketed by 648.41% to $102.4 million in 2023, then increased by 0.64% to $103.1 million in 2024, then tumbled by 32.51% to $69.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Non-Current Assets are $69.5 million (Q4 2025), $106.4 million (Q3 2025), and $110.5 million (Q2 2025).